Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was $451.2 for the day, up 1.70% from the previous closing price of $443.64. In other words, the price has increased by $1.70 from its previous closing price. On the day, 1.18 million shares were traded. ALNY stock price reached its highest trading level at $451.41 during the session, while it also had its lowest trading level at $444.28.
Ratios:
Our analysis of ALNY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 10.93 whereas as Long-Term Debt/Eq ratio is at 10.36.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’25 when Garg Pushkal sold 1,455 shares for $458.41 per share. The transaction valued at 666,987 led to the insider holds 20,221 shares of the business.
Garg Pushkal sold 1,396 shares of ALNY for $632,759 on Aug 18 ’25. The EVP Chief R&D now owns 21,676 shares after completing the transaction at $453.27 per share. On Aug 18 ’25, another insider, Tanguler Tolga, who serves as the EVP, Chief Commercial Officer of the company, sold 1,396 shares for $453.27 each. As a result, the insider received 632,759 and left with 29,466 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 59142844416 and an Enterprise Value of 59025002496. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.02 while its Price-to-Book (P/B) ratio in mrq is 235.83. Its current Enterprise Value per Revenue stands at 23.975 whereas that against EBITDA is -477.213.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.32, which has changed by 0.6074101 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $469.81, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is 23.39%, while the 200-Day Moving Average is calculated to be 57.73%.
Shares Statistics:
ALNY traded an average of 1.07M shares per day over the past three months and 1244500 shares per day over the past ten days. A total of 130.98M shares are outstanding, with a floating share count of 125.52M. Insiders hold about 4.24% of the company’s shares, while institutions hold 97.88% stake in the company. Shares short for ALNY as of 1755216000 were 3426778 with a Short Ratio of 3.02, compared to 1752537600 on 3379378. Therefore, it implies a Short% of Shares Outstanding of 3426778 and a Short% of Float of 3.45.
Earnings Estimates
Its stock is currently analyzed by 14.0 different market analysts. The consensus estimate for the next quarter is $2.25, with high estimates of $4.34 and low estimates of $0.68.
Analysts are recommending an EPS of between $6.54 and $2.88 for the fiscal current year, implying an average EPS of $3.92. EPS for the following year is $9.45, with 16.0 analysts recommending between $19.87 and $4.15.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 24 analysts. It ranges from a high estimate of $1.27B to a low estimate of $805M. As of the current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $500.92MFor the next quarter, 24 analysts are estimating revenue of $1.2B. There is a high estimate of $1.33B for the next quarter, whereas the lowest estimate is $928.13M.
A total of 26 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $3.82B, while the lowest revenue estimate was $3.39B, resulting in an average revenue estimate of $3.5B. In the same quarter a year ago, actual revenue was $2.25BBased on 27 analysts’ estimates, the company’s revenue will be $4.87B in the next fiscal year. The high estimate is $7.61B and the low estimate is $2.81B.
